HC 7366
Alternative Names: HC-7366Latest Information Update: 18 Feb 2026
At a glance
- Originator HiberCell
- Class Antineoplastics; Small molecules
- Mechanism of Action EIF2AK4 protein modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Bladder cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Renal cell carcinoma
- No development reported Solid tumours
Most Recent Events
- 11 Feb 2026 HiberCell plans a phase I SHARK trial for Renal cancer (Metastatic disease, Combination therapy) in USA (PO) in July 2026 (NCT07401875)
- 28 Mar 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO, Capsule)
- 17 Dec 2024 Chemical structure information added.